February 2026 Research Update

This month added a clearer real-world picture of how ravulizumab (a longer-acting complement C5 blocker) performed for adults starting their first C5 inhibitor for atypical HUS. In a US chart review, blood and kidney measures often improved quickly after treatment started and many people reached a combined measure called a complete TMA response within the first year. The overall pattern was early improvement followed by continued gains over months, though the study could not fully separate which patients had purely complement-driven disease.

In 79 adults, platelet counts and the blood marker LDH began normalizing in a noticeable minority by about the first week, and improvements in kidney function measures were also reported early. By 12 months, most patients with available data had normalized platelets and LDH, and many showed improved kidney function compared with before ravulizumab. The study also described changes in dialysis use, with many people who were on dialysis at the start not needing it during follow-up, while a small number started dialysis but were off it by month 12. [1]

For patients and caregivers, this report mainly adds confidence about what has been seen in trials: in routine US care, many people treated with ravulizumab showed improved blood counts and kidney function over time. Because this was a chart review without a comparison group and with missing data, it cannot prove ravulizumab caused every improvement, and it cannot predict an individual persons outcome. It may matter now as background information for understanding what has been observed with this medicine in everyday practice, while details like safety and which subgroups benefit most remain less clear in this dataset. [1]

This months case reports reinforced a recurring theme in atypical HUS: episodes can be triggered by major stressors such as pancreatitis, and complement testing and complement-blocking treatment were used as part of the response in some patients. Across these single-patient reports, the shared pattern was that complement activation markers were sometimes measured during the crisis and then improved as the patient recovered. These reports do not prove what will happen for others, but they make the real-world situations where aHUS-like TMA is considered feel more concrete.

In pancreatitis-associated complement-mediated TMA, one man received a single dose of eculizumab and had rapid improvement in platelets and kidney function within about a week, remaining in remission at 2 months. In that case, complement activation markers were elevated during the episode, supporting the idea that the complement system was active at that time. [2]

In a postpartum emergency where HELLP syndrome and extensive liver injury occurred, the authors used imaging plus repeated complement assessment to help distinguish causes of thrombotic microangiopathy and guide supportive care that included plasma exchange and corticosteroids. The patient recovered blood counts and kidney and liver function, and complement markers normalized over time, with no recurrent clotting events reported during follow-up. This recovery ultimately ruled out aHUS: the illness was caused by HELLP syndrome, a pregnancy complication that can look like aHUS. [3]

For patients, these reports mainly help explain why aHUS discussions often include triggers like severe inflammation or pregnancy-related complications and why the complement system is frequently part of the workup. The evidence here is early and individual, so it cannot tell how often these triggers lead to aHUS, or which exact treatments are necessary in a given situation. What it adds now is a clearer picture that some teams use complement markers and response over time to support decision-making in complex, high-risk episodes, but the best approach still depends on factors not answered by case reports. [2]

The postpartum case also highlights that some syndromes can overlap and look similar in the moment, which can make early labeling difficult. For caregivers, it may be helpful to know that recovery can involve careful monitoring across multiple organs and repeated labs rather than a single test that gives an immediate answer. [3]

Several reports this month focused less on a single treatment and more on how complicated the underlying causes of aHUS and related TMAs can be. The shared message was that aHUS-like illness can sit at the intersection of genetics, infections, autoimmune disease, and other rare conditions, which can make diagnosis and long-term expectations harder to predict. Together, these papers add examples of how teams tried to sort out the driver of TMA and what recovery looked like in different contexts.

One report described gallbladder Actinomyces infection (identified on tissue exam) occurring alongside pancreatitis, cholecystitis, and an aHUS picture, with recovery after gallbladder removal and prolonged antibiotics and no recurrence over 1 year. Genetic testing in that patient found complement pathway variants that the authors felt could increase vulnerability to complement-mediated TMA, although not every variant had a clearly known meaning. [4]

A pediatric report linked a rare C3 gene change to strong signs of complement activation during severe illness, including kidney and intestinal blood vessel injury seen on biopsy. The child improved after intensive care that included plasma exchange and eculizumab, and the authors noted the same C3 variant in an unaffected parent, emphasizing that carrying a variant does not always mean disease will occur. [5]

Another pediatric case highlighted diagnostic overlap: a boy had aHUS features early on, but later testing identified classic Fabry disease and a separate heart muscle condition related to an MYH7 variant. Even with enzyme replacement therapy for Fabry disease, kidney function progressed to end-stage kidney disease over 2 years and heart thickening persisted, showing how multiple rare diseases can combine to shape outcomes. [6]

A separate paper combined one lupus-related secondary TMA case with a literature review of published case reports of plasma exchange in secondary TMA. In the compiled case reports, improvement after plasma exchange was reported in many patients, but outcomes appeared to vary by underlying cause, with poorer results noted in malignancy-associated TMA. Because the evidence came from case reports, the paper also emphasized that stronger studies are still needed to know how well plasma exchange works in each situation. [7]

One transplant case report described a woman with end-stage kidney disease from aHUS who underwent living donor kidney transplant after desensitization while continuing eculizumab. Over 1 year she had stable graft function with biopsies showing no antibody-mediated rejection and no recurrence of TMA, despite a positive crossmatch before transplant. [8]

For patients and caregivers, the main practical meaning of these reports is that aHUS and related TMAs are not always one single straightforward diagnosis with one cause. Some cases involve infections, autoimmune disease, or more than one inherited condition, and genetics can raise risk without fully determining what will happen. These findings matter mostly as understanding and context now, while larger studies are needed to show how common these scenarios are and which test results best predict recurrence or long-term kidney outcomes. [4]

The genetics-focused pediatric report also helps clarify why families may see genetic results described as uncertain or incomplete: a variant can look suspicious in models and match complement activation in the body, but still need more proof to confirm its exact effect. The transplant case contributes an example of how recurrence prevention and rejection risk were monitored after transplant in a person with aHUS, but as a single case it cannot define expected outcomes for others. [5]